TCR 2020; 12(01): 1-20
DOI: 10.1055/a-1019-1794
Industrieinformationen
© Georg Thieme Verlag KG Stuttgart · New York

Idelvion® as a modern treatment option for haemophilia B (Sponsor: CSL Behring GmbH)

Further Information

Publication History

Publication Date:
22 January 2020 (online)

Zusammenfassung

Idelvion® (albutrepenonacog alfa, rIX-FP) is a long-acting recombinant factor IX (FIX) albumin fusion protein indicated for the treatment and prophylaxis of bleeding in patients with haemophilia B. It allows prophylaxis intervals of up to 14 days.* Compared with previous therapy, this fusion protein allows for a significant reduction in injection frequency while maintaining a favourable efficacy and safety profile.